A Randomized, Placebo-controlled Trial of the Analgesi Kinase Inhibitor, Losmapimod, in Patients With Neurop Radiculopathy

Clinical Journal of Pain 31, 283-293 DOI: 10.1097/ajp.0000000000000122

Citation Report

_		_		
$(\Box T)$	TIO	NI L	יחס(DT

#	Article	IF	CITATIONS
1	Clinical candidates of small molecule p38 MAPK inhibitors for inflammatory diseases. MAP Kinase, 2015, 4, .	0.3	16
2	Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations. Pain, 2016, 157, 1851-1871.	4.2	270
3	Targeting glia for bone cancer pain. Expert Opinion on Therapeutic Targets, 2016, 20, 1365-1374.	3.4	36
4	Microglial role in the development of chronic pain. Current Opinion in Anaesthesiology, 2016, 29, 584-589.	2.0	25
5	Breaking barriers to novel analgesic drug development. Nature Reviews Drug Discovery, 2017, 16, 545-564.	46.4	258
6	Neuropathic Pain Related with Spinal Disorders: A Systematic Review. Asian Spine Journal, 2017, 11, 661-674.	2.0	14
7	Mitogen-activated protein kinase phosphatase-3 (MKP-3) in the surgical wound is necessary for the resolution of postoperative pain in mice. Journal of Pain Research, 2017, Volume 10, 763-774.	2.0	7
8	Medicinal Chemistry Case History: Structure-Based Drug Design of Oral and Inhaled p38 MAP Kinase Inhibitors as Clinical Candidates. , 2017, , 408-430.		0
9	Recent development in antihyperalgesic effect of phytochemicals: anti-inflammatory and neuro-modulatory actions. Inflammation Research, 2018, 67, 633-654.	4.0	19
10	Microglial Modulation as a Target for Chronic Pain: From the Bench to the Bedside and Back. Anesthesia and Analgesia, 2019, 128, 737-746.	2.2	47
11	Why muâ€opioid agonists have less analgesic efficacy in neuropathic pain?. European Journal of Pain, 2019, 23, 435-454.	2.8	45
12	Neurotrophins, Cytokines, and Pain. , 0, , 770-816.		2
13	Placebo Response Reduction and Accurate Pain Reporting Training Reduces Placebo Responses in a Clinical Trial on Chronic Low Back Pain. Clinical Journal of Pain, 2020, 36, 950-954.	1.9	8
14	p38 mitogen-activated protein kinase and pain. Life Sciences, 2020, 256, 117885.	4.3	46
15	Spinal microglia-neuron interactions in chronic pain. Journal of Leukocyte Biology, 2020, 108, 1575-1592.	3.3	24
16	AAPT Diagnostic Criteria for Chronic Low Back Pain. Journal of Pain, 2020, 21, 1138-1148.	1.4	14
17	Effects of the COVID-19 pandemic on chronic pain in Spain: a scoping review. Pain Reports, 2021, 6, e899.	2.7	21
18	Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations. Pain Reports, 2021, 6, e896.	2.7	22

CITATION REPORT

#	Article	IF	CITATIONS
19	Spinal macrophages resolve nociceptive hypersensitivity after peripheral injury. Neuron, 2021, 109, 1274-1282.e6.	8.1	62
20	Comparing the efficacy of two different temperature stimulation in warm acupuncture on acute low back pain: A randomized controlled trial. Integrative Medicine Research, 2022, 11, 100748.	1.8	4
21	Clia and Orofacial Pain: Progress and Future Directions. International Journal of Molecular Sciences, 2021, 22, 5345.	4.1	19
22	Automated home-cage for the evaluation of innate non-reflexive pain behaviors in a mouse model of inflammatory pain. Scientific Reports, 2021, 11, 12240.	3.3	13
23	Glial and neuroimmune cell choreography in sexually dimorphic pain signaling. Neuroscience and Biobehavioral Reviews, 2021, 125, 168-192.	6.1	29
24	p38 MAPKs — roles in skeletal muscle physiology, disease mechanisms, and as potential therapeutic targets. JCI Insight, 2021, 6, .	5.0	35
25	Of Mice and Monkeys: Neuroprotective Efficacy of the p38 Inhibitor BIRB 796 Depends on Model Duration in Experimental Glaucoma. Scientific Reports, 2020, 10, 8535.	3.3	14
26	PKCζ-Mitogen-Activated Protein Kinase Signaling Mediates Crotalphine-Induced Antinociception. Toxins, 2021, 13, 912.	3.4	4
27	NSAIDs in sciatica (NIS): study protocol for an investigator-initiated multicentre, randomized placebo-controlled trial of naproxen in patients with sciatica. Trials, 2022, 23, .	1.6	2
28	Antinociceptive properties of losmapimod in two acute pain models in rats: behavioural analysis, immunohistochemistry, dose response, and comparison with usual analgesic drugs. , 2022, 3, 100029.		0
29	Posttranscriptional Regulation of Gene Expression Participates in the Myelin Restoration in Mouse Models of Multiple Sclerosis: Antisense Modulation of HuR and HuD ELAV RNA Binding Protein. Molecular Neurobiology, 2023, 60, 2661-2677.	4.0	3
30	Exploring Novel Therapeutic Targets in the Common Pathogenic Factors in Migraine and Neuropathic Pain. International Journal of Molecular Sciences, 2023, 24, 4114.	4.1	9
31	Analgesic Effects of Fisetin, Peimine, Astaxanthin, Artemisinin, Bardoxolone Methyl and 740 Y-P and Their Influence on Opioid Analgesia in a Mouse Model of Neuropathic Pain. International Journal of Molecular Sciences, 2023, 24, 9000.	4.1	2
32	Advances in Neuropathic Pain Research: Selected Intracellular Factors as Potential Targets for Multidirectional Analgesics. Pharmaceuticals, 2023, 16, 1624.	3.8	1
33	CNS-Active p38α MAPK Inhibitors for the Management of Neuroinflammatory Diseases: Medicinal Chemical Properties and Therapeutic Capabilities. Molecular Neurobiology, 0, , .	4.0	0
34	Microglial STINC activation alleviates nerve injury-induced neuropathic pain in male but not female mice. Brain, Behavior, and Immunity, 2024, 117, 51-65.	4.1	1